Stress-Induced Epinephrine Enhances Lactate Dehydrogenase A and Promotes Breast Cancer Stem-Like Cells by Cui, Bai et al.
University of Kentucky 
UKnowledge 
Molecular and Cellular Biochemistry Faculty 
Publications Molecular and Cellular Biochemistry 
3-2019 
Stress-Induced Epinephrine Enhances Lactate Dehydrogenase A 
and Promotes Breast Cancer Stem-Like Cells 
Bai Cui 
Dalian Medical University, China 
Yuanyuan Luo 
Dalian Medical University, China 
Pengfei Tian 
Dalian Medical University, China 
Fei Peng 
Dalian Medical University, China 
Jinxin Lu 
Dalian Medical University, China 
See next page for additional authors Follow this and additional works at: https://uknowledge.uky.edu/biochem_facpub 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Oncology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Cui, Bai; Luo, Yuanyuan; Tian, Pengfei; Peng, Fei; Lu, Jinxin; Yang, Yongliang; Su, Qitong; Liu, Bing; Yu, 
Jiachuan; Luo, Xi; Yin, Liu; Cheng, Wei; An, Fan; He, Bin; Liang, Dapeng; Wu, Sijin; Chu, Peng; Song, Luyao; 
Liu, Xinyu; Luo, Huandong; and Zhou, Binhua P., "Stress-Induced Epinephrine Enhances Lactate 
Dehydrogenase A and Promotes Breast Cancer Stem-Like Cells" (2019). Molecular and Cellular 
Biochemistry Faculty Publications. 190. 
https://uknowledge.uky.edu/biochem_facpub/190 
This Article is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge. 
It has been accepted for inclusion in Molecular and Cellular Biochemistry Faculty Publications by an authorized 
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Stress-Induced Epinephrine Enhances Lactate Dehydrogenase A and Promotes 
Breast Cancer Stem-Like Cells 
Digital Object Identifier (DOI) 
https://doi.org/10.1172/jci121685 
Notes/Citation Information 
Published in The Journal of Clinical Investigation, v. 129, no. 3. 
This work is licensed under the Creative Commons Attribution 4.0 International License. 
The first 20 authors and the author from the University of Kentucky are shown on the author list above. 
Please refer to the downloaded document for the complete author list. 
Authors 
Bai Cui, Yuanyuan Luo, Pengfei Tian, Fei Peng, Jinxin Lu, Yongliang Yang, Qitong Su, Bing Liu, Jiachuan Yu, 
Xi Luo, Liu Yin, Wei Cheng, Fan An, Bin He, Dapeng Liang, Sijin Wu, Peng Chu, Luyao Song, Xinyu Liu, 
Huandong Luo, and Binhua P. Zhou 
This article is available at UKnowledge: https://uknowledge.uky.edu/biochem_facpub/190 
Stress-induced epinephrine enhances lactate dehydrogenase A
and promotes breast cancer stem-like cells
Bai Cui, … , Keith W. Kelley, Quentin Liu
J Clin Invest. 2019;129(3):1030-1046. https://doi.org/10.1172/JCI121685.
  
Graphical abstract
Research Article Metabolism Oncology
Find the latest version:
https://jci.me/121685/pdf
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 0 3 0 jci.org   Volume 129   Number 3   March 2019
Introduction
Patients suffering from cancer often experience a variety of 
chronic emotional stressors (1), including depression, anxiety, 
and fear (2, 3). These serve as risk factors by facilitating tumor 
growth and increasing expression of invasion-related genes that 
promote cancer progression (4). Indeed, chronic stress increases 
catecholamine levels and promotes tumor burden and invasive 
growth of ovarian carcinoma cells in vivo (5). Moreover, stress- 
induced hormones have been shown to increase cancer cell dis-
semination in pancreatic cancer (4). Immune activity has long 
been established as being suppressed by chronic stress and is 
considered to be responsible for promoting cancer (6, 7). Yet, 
the direct signaling network between stress pathways and a 
cancer-propagating program remains almost completely unknown.
Cancer stem-like cells (CSCs) are characterized by an 
increased capability of self-renewal (8) and tumor reconstitution 
(9). They are able to generate heterogeneous lineages of cancer 
cells that constitute tumors. These CSCs are important for the ini-
tiation, maintenance, and clinical outcome of many cancers. Pre-
vious studies have demonstrated that transcription factors such 
as MYC, SLUG, and SOX2 are responsible for tumorigenesis and 
can reprogram cells from a differentiated to a stem-like state in a 
variety of cancers (10–12). Indeed, the transcription factor MYC 
plays key roles in oncogenesis and is involved in many cancer net-
works (13). MYC increases SOX2 transcriptional activity, form-
ing a positive-feedback loop involving the Wnt/β-catenin/MYC/
SOX2 axis, which defines a highly tumorigenic cell subpopulation 
in ALK-positive anaplastic large cell lymphomas (14). Moreover, 
SOX2 represses microRNA-452 (miR-452), which acts as a metas-
tasis suppressor to directly target the SLUG 3′-untranslated region 
(3′-UTR). Taken together with miR-452 loss and SLUG upregu-
lation, SOX2 provides a potentially novel mechanism by which 
CSCs acquire metastatic potential (15).
Lactate dehydrogenase A (LDHA) executes the final step of 
the Warburg effect by converting pyruvate to lactate. Moreover, 
LDHA-associated lactic acid production leads to a relatively low 
pH, allowing cancer cells to survive immune evasion via diminish-
ing nuclear factor of activated T cells (NFAT) levels and T and NK 
cell activation (16, 17). Deregulation of LDHA has been reported 
in a number of malignancies, including prostate, breast, hepato-
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At the lowest number of implanted tumor cells (102), primary 
stressed tumor cells increased tumor formation efficiency from 
20% to 70% in secondary control mice, and enhanced tumor for-
mation efficiency to 100% in secondary stressed mice (Table 1). 
As expected, tumor formation in control and stressed mice did not 
differ at the highest dose of tumor cells (105; 80% in control vs. 
100% in stressed mice).
Immediately after the last day of stress, we collected blood 
from all mice. Subsequently, we examined the serum concentra-
tion of the major adrenal stress hormones, including cortisol, nor-
epinephrine, and epinephrine (23). Serum levels of epinephrine 
displayed a sharp increase in the stress-induced group compared 
with those with control treatment, whereas serum levels of cor-
tisol did not differ significantly between groups (Figure 1E). We 
then monitored xenograft growth in NOD/SCID mice injected 
with epinephrine. We found that tumors from epinephrine-treated 
mice were larger than those from PBS-treated mice, an effect that 
occurred as soon as 15 days following tumor implantation (Supple-
mental Figure 2A). Both diameter and number of mammospheres 
derived from the epinephrine-injected group were significantly 
increased compared with those from PBS-treated control mice 
(Supplemental Figure 2B). Consistently, epinephrine increased 
the expression of self-renewal factors in a dose-dependent man-
ner (Figure 1F). Norepinephrine marginally enhanced but cortisol 
had no effect on the expression of self-renewal factors (Supple-
mental Figure 2, C and D).
Following injection of propranolol, an antagonist of adren-
ergic β-receptors (ADRBs), stressed mice demonstrated a sig-
nificant decrease in tumor volume when compared with the 
stress-only control group (Figure 1G). Notably, treatment with 
propranolol caused a substantial reduction in tumor formation 
efficiency and blocked stress-induced tumorigenesis (Tables 2 
and 3). The potential role of ADRB1 or ADRB2 was then deter-
mined by silencing of ADRB1 and ADRB2 with small interfering 
RNA (siRNA). This approach significantly blunted the stem-like 
cell phenotype (Supplemental Figure 2, E and F). ADRB2 deple-
tion efficiently blocked the epinephrine-induced enhancement 
of breast CSCs (BCSCs) (Figure 1H and Supplemental Figure 
2G), whereas ADRB1 knockdown did not (Supplemental Figure 
2H). Similarly, the ADRB2 inhibitor ICI118,551 blocked the 
epinephrine-increased β-catenin, OCT-4, and NANOG expres-
sion, whereas the ADRB1 inhibitor atenolol only had a marginal 
effect (Supplemental Figure 2I). Further investigation demon-
strated a similar reduction in tumor burden with the ADRB2 
antagonist ICI118,551 (Figure 1I and Supplemental Figure 2J).
Following stress treatment for 5 weeks in the metastatic mouse 
model, we found that stressed mice displayed more lung meta-
static lesions as assessed by CT scans. Nodules on the surface of 
lungs were counted, which revealed more nodules in the lungs of 
stressed compared with control mice (Supplemental Figure 2K). In 
contrast, shMYC- and shSLUG-mediated depletion reversed the 
ability of stress to enhance lung metastasis. These data indicate 
that chronic stress promotes the potential metastasis of cancer via 
MYC and SLUG. Furthermore, epinephrine-treated cells showed 
increased migration, invasion, and wound-healing abilities (Sup-
plemental Figure 2, L and M). We also performed immunohisto-
chemistry to examine changes in SNAIL1 and TWIST expression in 
cellular, and gastrointestinal cancers (18–20). Inhibition of LDHA 
reduces malignant transformation and delays tumor formation, 
indicating an important role for LDHA in tumor initiation and pro-
gression (21). As might be predicted, LDHA consistently elevates 
“stemness” properties of CSCs and enhances spheroid formation 
in hepatocellular cancer (22). In this work, we define what to our 
knowledge is a novel molecular pathway by which chronic stress 
acts via β2-adrenergic receptor to elevate LDHA. This leads to a 
switch to lactate production, and the adjusted pH then directs 
USP28-mediated deubiquitination and stabilization of MYC, 
thereby promoting stem-like traits in breast cancer. These data 
provide what to our knowledge is a novel pathway that explains 
how chronic stress promotes breast cancer progression by acting 
directly on CSCs.
Results
Chronic stress promotes breast cancer stem-like traits via epi-
nephrine-ADRB2. As described previously (5), we adapted an 
accepted chronic stress model to nonobese diabetic–severe 
combined immunodeficient (NOD/SCID) mice and examined 
the effects of stress on both tumor growth and CSC self-renewal 
ability (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI121685DS1). 
Beginning from 15 days after cancer cell implantation, tumors 
from stressed mice were larger than those from control mice 
(Figure 1A and Supplemental Figure 1B). Even though there was 
no difference in body weight between the control and stressed 
groups (Supplemental Figure 1C), tumors from the chronic stress 
group continued to increase throughout the entire 30-day stress 
paradigm. Subsequently, mice were subjected to behavioral 
assays using both the tail suspension test and the open field test. 
Chronically stressed mice exhibited more anxiogenic and depres-
sion-like behaviors than control mice (Supplemental Figure 1, D 
and E). Consistently, C57BL/6 mice, the immunocompetent 
mice, were injected with E0771 and Py8119 cells under stress. 
The results indicated that stress enhanced the tumor burden in 
the C57BL/6 mouse model (Supplemental Figure 1F).
After euthanasia in order to collect the xenografted tumors, 
we found that stress-induced tumors expressed significantly high-
er levels of self-renewal genes. These included CTNNB, POU5F1, 
and NANOG, as measured by both mRNA (Supplemental Figure 
1G) and protein expression (Figure 1B and Supplemental Figure 
1H). Similar results were also observed by immunohistochemical 
analyses (Figure 1C and Supplemental Figure 1I). Next, single-cell 
suspensions were prepared by enzymatic digestion from xeno-
grafts of both control and stressed mice. Mammosphere trans-
plantation assays were used to assess their self-renewal abilities 
in vitro. Tumor cells from the stressed group displayed greater 
mammosphere-forming efficiencies in both the primary and sec-
ondary generations, as indicated by a significant increase in both 
spheroid diameter and number (Figure 1D and Supplemental 
Figure 1J). Stress significantly increased sphere formation fre-
quencies of primary tumor cells as examined by in vitro limiting 
dilution assays (Supplemental Figure 1K). In vivo, serially diluted 
primary tumor cells were subcutaneously inoculated at 4 different 
sites into each group of secondary mice (Supplemental Figure 1L). 
Notably, tumor formation rates of stressed mice were increased. 
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Chronic stress–induced MYC activates SLUG transcription to 
stimulate CSCs. In order to investigate the downstream targets 
responsible for the increase in stress-mediated stem-like prop-
erties in breast cancer, we used Affymetrix Human PrimeView 
(analyzed from independent triplicates) to perform a large-scale 
stressed tumor tissues. The results indicated enhanced expression 
of SNAIL1 and TWIST in stressed tumors compared with control 
tumors (Supplemental Figure 2N). Collectively, these data demon-
strate that chronic stress–induced epinephrine promotes breast 
cancer stem-like properties by acting through ADRB2 (Figure 1J).
Figure 1. Chronic stress promotes ADRB2-dependent cancer stem cell–like properties in vivo. (A) Tumor growth of MDA-MB-231 tumors in control (Ctrl) 
and stressed mice; n = 5 (1-way ANOVA). (B–D) Primary MDA-MB-231 tumors from the Ctrl and stress groups were subjected to immunoblot (C, control; 
S, stressed) (B), immunohistochemical staining (scale bar: 50 μm; original magnification, ×20, ×40, ×96 [insets]) (C), and primary and secondary spheroid 
formation; n = 5 (1-way ANOVA) (D). (E) Concentrations (pg/ml) of cortisol (Cort), norepinephrine (NE), and epinephrine (Epi) in serum of Ctrl and stress mice 
after the last day of stress; n = 5 (Student’s t test). (F) Immunoblot analysis of indicated antibodies in MDA-MB-231 cells treated with indicated concen-
trations of Epi. (G) Growth of Ctrl, propranolol (Pro), stress, and stress-induced propranolol-treated (Pro + stress) MDA-MB-231 tumors in mice; n = 6 (1-way 
ANOVA). (H) MDA-MB-231 cells were transfected with siADRB2 and then treated with Epi for 5 days. Expression of proteins was determined by immunoblot 
analysis. (I) Growth of MDA-MB-231 tumors in Ctrl and stress mice in the presence or absence of ICI118,551 (ICI); n = 5 (1-way ANOVA). (J) Model of chronic 
stress–mediated cancer stem-like traits mediated by β2-adrenergic receptor (ADRB2) signaling. Data are representative of at least 3 independent experi-
ments. Data represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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these findings, activity of the truncated SLUG promoter (–496 
to 0 bp) was enhanced upon epinephrine exposure, but it was 
reversed upon MYC knockdown (Figure 2F).
To further define the binding sites of MYC in transactivating 
SLUG, we constructed 3 MYC-responsive element mutants, –57/ 
–54 (Mut1, CGTG to TTTT), –104/–101 (Mut2, CACG to TTTT), 
and –412/–408 (Mut3, CGTGG to TTTTT), and subcloned them 
into a luciferase vector. Luciferase reporter assays showed that the 
responsive element corresponding to Mut3 was responsible for 
induction of MYC by epinephrine (Figure 2G and Supplemental 
Figure 3J). We performed chromatin immunoprecipitation (ChIP) 
assays using a MYC antibody and confirmed that MYC directly 
binds to the –496 to –394 region of the endogenous SLUG pro-
moter, whereas there was no binding in the –394 to 0 region of 
the SLUG promoter (Figure 2H). These findings demonstrate that 
MYC directly binds to the SLUG promoter and transactivates its 
expression under epinephrine treatment (Figure 2I).
USP28 directly deubiquitinates and stabilizes MYC. To examine 
the effects of chronic stress–induced epinephrine on MYC expres-
sion, we analyzed MYC mRNA and protein levels following epineph-
rine treatment for 5 days. Epinephrine led to a significant increase 
in MYC protein (Figure 3A) but revealed no change in MYC mRNA 
(Supplemental Figure 4A). We next treated cells with the protein 
synthesis inhibitor cycloheximide to determine whether epineph-
rine regulates MYC protein degradation. Indeed, MYC protein levels 
exhibited a gradual decrease in the absence of epinephrine, whereas 
MYC degradation was significantly attenuated in the presence of 
epinephrine (Figure 3B and Supplemental Figure 4B). These results 
indicate that epinephrine enhances the stability of MYC protein.
As rapid MYC protein turnover can be mediated by the 
ubiquitin-dependent proteasome pathway (26, 27), we treated 
cells with the proteasome inhibitor MG132 in the presence of 
epinephrine. Interestingly, MG132 enhanced MYC expression, 
whereas epinephrine did not obviously increase MYC level under 
MG132 treatment (Figure 3C), suggesting that epinephrine sta-
bilizes MYC through inhibition of the proteasome-dependent 
degradation pathway. We next coexpressed His-MYC and HA- 
ubiquitin in 293T cells, followed by treatment with epinephrine in 
the presence or absence of MG132. MYC was heavily ubiquitinat-
ed in MG132-treated cells, but was significantly reduced following 
epinephrine treatment (Supplemental Figure 4C). These results 
suggest that epinephrine stabilizes MYC by eliminating its ubiq-
uitination and consequent degradation.
MYC ubiquitination is a dynamic process involving ubiquitin 
ligases and deubiquitinases (DUBs) (28). We identified the deu-
biquitinase USP28 as a key candidate that reverses epinephrine- 
enhanced MYC expression by overexpressing E3 ligases or knock-
down of DUBs (Figure 3D). As expected, depletion of USP28 
remarkably decreased MYC protein and reversed epinephrine-in-
duced increase in MYC protein expression (Supplemental Figure 
4D and Figure 3E), whereas overexpression of USP28 enhanced 
MYC expression (Supplemental Figure 4E). We further verified that 
USP28 knockdown reduced epinephrine-induced MYC stabiliza-
tion and directly bound to MYC box I through its USP domain with-
out FBW7 (Figure 3F and Supplemental Figure 4, F–K).
To further investigate the functional impact of mutant USP28 
(USP28Mut) in which the catalytic cysteine has been replaced by 
expression profile analysis (Figure 2A). To further analyze the 
functional importance of the altered gene sets (Table 4), we 
performed Gene Ontology (GO) analysis including Biochem-
ical Process, Cell Component, and Molecular Function, and 
found that some important metabolic processes and cell migra-
tion were among the top 10 of GO analysis (Supplemental Fig-
ure 3A). Moreover, comparing the significantly altered genes in 
microarray data with the Cancer Stem Cells Therapeutic Target 
Database (24) and stem-like cell gene sets (8), we found that 4 
stemness-associated genes displayed significantly altered 
expression levels in epinephrine-induced tumors. Further veri-
fication of these genes in epinephrine-treated cells showed that 
SLUG, a key regulatory factor in breast cancer stemness (25), 
exhibited the greatest increase in cells following epinephrine 
treatment (Figure 2B). Using 3 different inhibitory shRNAs, we 
found that ablation of SLUG decreased expression of the stem-
ness proteins β-catenin, OCT-4, and NANOG (Supplemen-
tal Figure 3B). Consistently, depletion of SLUG dramatically 
reversed epinephrine-improved mammosphere formation abil-
ity (Figure 2C and Supplemental Figure 3C) as well as chronic 
stress–induced tumor progression (Figure 2D). SLUG knock-
down also inhibited the epinephrine-induced increased expres-
sion of β-catenin, OCT-4, and NANOG (Supplemental Figure 
3D). These data suggest that SLUG plays a key role in the mainte-
nance of stress-induced breast cancer stem-like properties.
To explore how SLUG mRNA is regulated, we evaluated the 
half-life of SLUG mRNA in the presence and absence of epineph-
rine. We found that epinephrine had no significant effect on the 
half-life of SLUG mRNA (Supplemental Figure 3E). Then, using 
a luciferase reporter assay, we found that the SLUG promoter 
(–2121 to 0 bp) is activated by epinephrine. Serial truncated anal-
ysis of the SLUG promoter (–1497 to 0, –997 to 0, –496 to 0 bp) 
revealed that the –496 to 0 bp region of the SLUG promoter is 
required for epinephrine-mediated SLUG transactivation (Figure 
2E). Furthermore, by analysis of the SLUG promoter sequence 
(–496 to 0 bp) using the JASPAR database (Supplemental Fig-
ure 3F), MYC was identified to be the most probable candidate 
responsible for SLUG transactivation. As expected, overexpres-
sion or depletion of MYC remarkably increased and decreased, 
respectively, both SLUG mRNA and SLUG protein expression 
(Supplemental Figure 3, G and H). SLUG promoter activity was 
dramatically enhanced or suppressed following up- or downreg-
ulation of MYC (Supplemental Figure 3I). In concordance with 
Table 1. Serial dilution tumorigenesis
Inoculation CtrlA StressA
CtrlB CtrlB StressB
1 × 102 20% 70% 100%
1 × 103 40% 70% 100%
1 × 104 60% 100% 100%
1 × 105 80% 100% 100%
Statistical analysis for tumorigenesis with the cell numbers and 
treatments indicated. APrimary treatment of mice; BSecondary treatment 
of mice. n = 5. 
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This result is also confirmed by a distance diagram for the 
USP28WT/Mut catalytic domain following MD simulation for 150 
nanoseconds (Supplemental Figure 4, L–N). In addition, the 
root-mean-square fluctuation profiles demonstrated greater 
fluctuations in the USP28WT than in the mutant USP28Mut, a 
finding that suggests more favorable binding of USP28WT to 
the MYC46–74 motif (Supplemental Figure 4O). These results 
explained how a single mutation in USP28 leads to a rather unfa-
alanine (C171A), different models of binding between USP28WT 
or USP28Mut and MYC46–74 amino acids were assessed using mac-
romolecular modeling and molecular dynamics (MD) simulation 
approaches (29). We obtained conformational free-energy surfaces 
of USP28WT and USP28Mut with the MYC motif using fully atomistic 
explicit-solvent force fields. This finding indicates a more favor-
able binding interaction between USP28WT and MYC than between 
USP28Mut and MYC (Figure 3G).
Figure 2. Chronic stress–induced MYC activates SLUG transcription to stimulate CSCs. (A) A cluster heatmap of expression profiles of mRNAs in PBS- and 
Epi-treated MDA-MB-231–derived tumors; n = 3. (B) Comparison of array data (fold change >2, Q < 0.05, 54 genes) with stem-like cell genes (405 genes). 
Common genes were verified by Epi treatment and are listed in the column according to fold change. n = 3. (C) Distribution patterns and number (d > 50 
μm) of mammospheres from the negative control (shNC) or shSLUG MDA-MB-231 cells after treatment with PBS or Epi for 5 days; n = 3 (1-way ANOVA).  
(D) Growth of shNC or shSLUG-3 MDA-MB-231 tumors in mice with or without stress treatment; n = 6 (1-way ANOVA). (E) Dual-luciferase reporter assays of 
MDA-MB-231 cells transfected with SLUG truncated promoters or empty vector (EV) in the presence or absence of Epi for 5 days; n = 3 (1-way ANOVA). (F) 
Dual-luciferase analysis in shNC or shMYC MDA-MB-231 cells treated with PBS or Epi for 5 days and transfected with EV or SLUG promoter (–496 to 0);  
n = 3 (1-way ANOVA). (G) Dual-luciferase reporter assays of MDA-MB-231 cells treated with Epi for 5 days and transfected with SLUG WT, mutant 1 (Mut1, 
–57 to –54), mutant 2 (Mut2, –104 to –101), or mutant 3 (Mut3, –412 to –408) promoters; n = 3 (1-way ANOVA). (H) ChIP-PCR analysis in MDA-MB-231 cells 
of MYC occupancy on the SLUG promoter. (I) Model of Epi-induced cancer stem-like traits through MYC/SLUG signaling. Data are representative of at least 
3 independent experiments. Data represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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vorable binding between USP28Mut and MYC, indicating that the 
Cys171 residue of USP28 is critical for binding MYC (Supplemen-
tal Videos 1 and 2). We then cotransfected USP28WT or USP28Mut 
along with His-MYC and HA-ubiquitin into 293T cells. Ubiq-
uitination assays showed that USP28Mut markedly increased 
MYC ubiquitination level compared with USP28WT and reversed 
the epinephrine-inhibited ubiquitin level of MYC (Figure 3H). 
In agreement, USP28 knockdown decreased mammosphere 
diameter and number (Figure 3I and Supplemental Figure 4P). 
Together, these findings illustrate that epinephrine stabilizes 
MYC protein by inducing USP28 and that USP28 Cys171 directly 
interacts with the MYC MBI domain (Figure 3J).
Chronic stress recruits glycolytic activator LDHA to promote glu-
cose metabolic rewiring. Metabolic reprogramming toward aero-
bic glycolysis and biomass accumulation is known to accompany 
tumorigenesis (30). We therefore decided to study the role of glu-
cose metabolism following chronic stress. Epinephrine-treated 
cells increased glucose and lactate levels and decreased cellular 
ATP compared with control cells (Figure 4A). Epinephrine-treated 
cells exhibited an increased extracellular acidation rate and 
decreased oxygen consumption rate (Supplemental Figure 5A). 
Moreover, using targeted capillary electrophoresis–mass spec-
trometry (CE-MS), we extracted 54 metabolites and found a signif-
icant increase in the levels of glycolytic metabolites in epinephrine- 
Figure 3. Chronic stress–induced USP28 stabilizes MYC and promotes CSCs. (A) Immunoblots of MYC in MDA-MB-231 and MCF-7 cells treated for 5 days 
with PBS or Epi. (B) MDA-MB-231 cells were treated with Epi for 5 days followed by treatment with cycloheximide (CHX) for the indicated times. The intensi-
ty of MYC expression for each time point was quantified by densitometry and plotted against time. (C) Immunoblots of MDA-MB-231 cells treated with Epi 
for 5 days and then incubated with or without MG132 for 6 hours. (D) Fold change of immunoblots of MDA-MB-231 cells transfected with indicated plasmids 
followed by treatment with Epi for 5 days; n = 3 (Student’s t test). (E) Immunoblot analysis of MDA-MB-231 cells transfected with USP28 siRNA-2 followed 
by treatment with PBS or Epi for 5 days. (F) Immunoprecipitation of USP28 constructs and MYC (amino acids 1–95) in 293T cells. (G) Free-energy surface of 
the USP28WT-MYC46–74 complex and USP28Mut-MYC46–74 complex (top panel). Gray cartoons, USP28WT/Mut structures; red spheres, side chain of His600 and Cys/
Ala171; green cartoons, MYC motifs; blue spheres, Lys51 and Lys52 in MYC motif. (H) Ubiquitin assays of 293T cells transfected with MYC and WT or a C171A 
mutant (Mut) of USP28 followed by treatment with Epi. (I) Distribution patterns and number (d > 50 μm) of mammospheres from cells in E; n = 3 (1-way 
ANOVA). (J) Model of Epi-induced cancer stem-like traits through USP28/MYC/SLUG signaling. Data are representative of at least 3 independent experi-
ments. Data represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
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treated compared with PBS-treated cells (Figure 4B and Supple-
mental Figure 5B). To further explore the differentially expressed 
genes of glycolysis enzymes in CSCs, we analyzed 4 publicly acces-
sible Gene Expression Omnibus (GEO) data sets of different cell 
models with replicates. We discovered that glycolysis-associated 
genes were enriched in a cancer stem cell population (Figure 4C). 
These data suggest that epinephrine switches glucose metabolism 
from homeostasis to glycolysis.
To examine the underlying cause for this switch, expression of 
several key glycolytic enzymes following epinephrine treatment were 
examined, including HK2, PFKM, PKM2, LDHA, and PDK1. We 
observed that both HK2 and LDHA increased in response to epineph-
rine (Figure 4D and Supplemental Figure 5C). However, norepineph-
rine promoted the expression of PFKM and HK2, but not USP28, 
MYC, or SLUG. In addition, cortisol had no effect on these key reg-
ulators (Supplemental Figure 5D). Also, high glucose consistently 
triggered HK2 and LDHA expression and stimulated the USP28/
MYC axis in breast cancer cells (Supplemental Figure 5E). Silencing 
of LDHA significantly reversed induction of USP28 and MYC by epi-
nephrine (Figure 4E), while silencing of HK2 displayed no change on 
the effect of epinephrine (Supplemental Figure 5F). Together, these 
findings illustrate that epinephrine enhances USP28 expression via 
induction of LDHA and metabolic rewiring (Figure 4F).
LDHA generating lactate enhances the USP28 signaling. To 
examine the effects of chronic stress–induced epinephrine on 
USP28 expression, we conducted quantitative PCR and found 
that LDHA knockdown had no significant effect on USP28 mRNA 
expression (Supplemental Figure 6A). To test the possibility that 
LDHA affects USP28 stability, we treated cells with cyclohexim-
ide and found that the half-life of USP28 was shortened in LDHA- 
Figure 4. Chronic stress elevates LDHA to enhance glycolysis. (A) Glucose uptake, lactate production, and cellular ATP were measured in MCF-7 and MDA-
MB-231 cells treated with PBS or Epi for 5 days; n = 3 (Student’s t test). (B) Representative heatmap of metabolome profiles (top panel). Heatmap colors 
represent relative metabolite levels as indicated in the color key. Average fold change of glycolytic metabolites was measured by capillary electrophoresis–
mass spectrometry (bottom). G-6-P, glucose-6-phosphate; F-6-P, fructose-6-phosphate; FBP, fructose-1,6-phosphate. n = 3 (Student’s t test). (C) Relative 
mRNA expression of indicated genes in 4 GEO databases analyzed by GEO2R. (D) Immunoblot analysis of MDA-MB-231 cells treated with PBS or Epi for 5 
days. (E) Immunoblot analysis of MDA-MB-231 and MCF-7 cells transfected with siLDHA in the presence or absence of Epi for 5 days. (F) Model of Epi- 
induced USP28/MYC signaling through LDHA-mediated metabolic rewiring. Data are representative of at least 3 independent experiments. Data represent 
mean ± SEM; *P < 0.05, **P < 0.01.
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Patients with high serum epinephrine exhibited lower overall 
survival (OS) rate and disease-free survival (DFS) rate compared 
with patients with low epinephrine levels (Figure 6D). Mean-
while, Cox regression analysis showed that low serum epineph-
rine is a significant predictor of both longer OS and DFS (Table 
6). We then divided 71 breast cancer samples into 2 groups, 
LDHAlo and LDHAhi, by immunohistochemistry grade (data not 
shown) based on the ROC curve analysis (Supplemental Figure 
7D). As predicted, the LDHAhi group showed lower OS and DFS 
rates compared with the LDHAlo group (Figure 6E). Notably, the 
Epilo and LDHAlo groups displayed a more favorable prognosis 
than the Epihi and LDHAhi groups, supporting the significant cor-
relation between serum epinephrine levels and LDHA expres-
sion (Figure 6F).
Vitamin C is a promising intervention for breast cancer patients 
with chronic stress. To identify a potential therapeutic agent for 
patients undergoing chronic stress, we conducted a screen based 
on the US drug collection of compounds. To this end, MDA-
MB-231 cells stably expressing the EGFP-LDHA fusion protein 
were incubated with different compounds for 6 (1 μM or 2 μM) 
or 12 hours (1 μM) (Figure 7A). The screening identified 18 com-
pounds that lowered fluorescence of EGFP-LDHA, including vita-
min C (Figure 7B and Supplemental Figure 8A). Virtual screening 
of 2037 FDA-approved drugs against LDHA also revealed that 
vitamin C was among the 7 vitamins in the top 200 hits (Supple-
mental Figure 8B). Furthermore, vitamin C has no effect on cell 
viability at the experimental doses and time courses used (Sup-
plemental Figure 8C). We next examined the impact of vitamin 
C on epinephrine-induced LDHA/USP28/MYC/SLUG signaling 
by Western blot analysis and found that vitamin C attenuated the 
epinephrine-induced increase in LDHA, USP28, MYC, and SLUG 
expression (Figure 7C).
The potential impact of vitamin C on LDHA activity was then 
examined. We found that vitamin C suppressed lactate production 
in both the absence and the presence of epinephrine (Figure 7D 
and Supplemental Figure 8D). In addition, vitamin C significantly 
caused a similar inhibition of BCSCs in the sphere formation assay 
(Figure 7E). Next, we injected vitamin C to determine whether it 
would inhibit tumor progression caused by chronic stress. Com-
pared with the control stressed group, mice treated additionally 
with vitamin C showed a significant reduction in tumor volume 
(Figure 7F and Supplemental Figure 8E). We also generated an 
MDA-MB-231 shLDHA cell line for tumor formation assays. Inter-
estingly, knockdown of LDHA had an effect similar to that of vita-
min C treatment, in which the stressed mice displayed an obvious 
reduction in tumor volume compared with untreated controls 
(Figure 7F). Taken together, these findings show that lowering of 
LDHA by vitamin C reduces tumorigenicity and that vitamin C 
might be a novel and effective therapeutic agent for targeting can-
cer in patients undergoing chronic stress (Figure 7G).
Discussion
Chronic stress is associated with aberrantly persistent activation 
of the hypothalamic-pituitary-adrenal axis, leading to enhanced 
production of cortisol and the simultaneous elevation of cate-
cholamines (23). We find that chronic stress promotes tumor 
progression in both immunocompetent and immunocompro-
depleted cells (Figure 5A). Moreover, the reduction in expression 
of USP28 caused by LDHA knockdown was reversed by MG132 
(Figure 5B). LDHA ablation also rescued USP28 ubiquitination 
that was inhibited by epinephrine (Figure 5C). Following treat-
ment with the LDHA inhibitor sodium oxamate, we found a reduc-
tion in USP28 stabilization induced by LDHA in a dose-dependent 
manner (Figure 5D and Supplemental Figure 6B).
To explore whether LDHA stabilizes USP28 expression 
through its major product lactate, we treated cells with lactate and 
found that it substantially increased USP28 protein (Figure 5E) 
and prolonged the half-life of USP28 (Supplemental Figure 6C). 
Importantly, USP28WT remarkably increased protein expression 
of MYC, whereas USP28Mut reversed lactate-induced MYC and 
SLUG (Figure 5F). Furthermore, we found that lactate enhanced 
the interaction of MYC only with USP28WT. However, there was 
no interactive effect when the USP28Mut was tested (Figure 5G and 
Supplemental Figure 6D). Interestingly, the lactate-induced weak 
acidic environment promoted USP28 signaling as well as hydro-
chloric acid and acetic acid (Figure 5H). Moreover, the pH 6.4 con-
dition provides a closer distance between the MYC motif and the 
USP28 catalytic domain than a neutral pH 7.4. This finding impli-
cates a much more stable binding and more efficient deubiquiti-
nation in a weak acidic environment (Figure 5I, Supplemental Fig-
ure 6E, and Supplemental Video 3). In accord with these data, the 
concentration of serum lactate was significantly higher in stressed 
mice compared with control mice (Figure 5J). Collectively, these 
data suggest that lactate enhances the USP28-MYC interaction via 
generation of a local acidic microenvironment (Figure 5K).
High serum epinephrine is associated with poor prognosis and 
activated LDHA/USP28/MYC/SLUG signaling axis in breast can-
cer patients. To evaluate the clinical relevance of circulating epi-
nephrine, we studied the relationship between epinephrine and 
clinical pathological parameters in 83 breast cancer patients 
using serum samples and paraffin-embedded tissues, respec-
tively. We first determined serum epinephrine concentrations 
by ELISA and divided the patients into 2 groups, Epilo and Epihi, 
based on receiver operating characteristic (ROC) curve analysis 
(Supplemental Figure 7A). The relationship between serum epi-
nephrine levels and clinical pathological parameters of breast 
cancer patients were then analyzed (Table 5). High epinephrine 
levels were not significantly correlated with tumor stage, node 
stage, or other clinical pathological characteristics (HER2, ER, 
and PR) (Table 5). Immunohistochemical staining was per-
formed on these tissues, and the results revealed that high serum 
epinephrine was positively associated with high LDHA, USP28, 
MYC, and SLUG protein expression (Figure 6A and Supplemen-
tal Figure 7B). We next collected 5 pairs of breast cancer and 
adjacent normal tissues and conducted Western blot analysis. 
All breast cancer tissues displayed higher LDHA and USP28 pro-
tein levels when compared with adjacent normal tissues (Figure 
6B and Supplemental Figure 7C). In addition, quantitative PCR 
analysis showed that MDA-MB-231 sphere–enriched cells dis-
played higher LDHA-USP28-SLUG expression compared with 
MDA-MB-231-2D cells (Figure 6C). These findings suggest that 
high serum epinephrine is positively related to LDHA/USP28/
MYC/SLUG signaling and that LDHA can be a potential inde-
pendent prognostic factor for breast cancer.
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cancer stem-like traits. In a drug screen that targeted LDHA, 
we identified vitamin C as an agent capable of reversing the 
chronic stress–induced cancer stem-like phenotype. These find-
ings demonstrate the involvement of psychological factors in 
promoting stem-like properties in breast cancer cells and pro-
moting their tumorigenic potential. The mechanism is mediated 
by an LDHA-mediated glycolysis-dependent pathway. Impor-
tantly, we suggest that vitamin C, which targets this pathway by 
mised mouse models. Furthermore, using a NOD/SCID mouse 
model, we show that chronic stress increases epinephrine levels 
and activates β2-adrenergic receptor to promote breast cancer 
stem-like properties via metabolic rewiring. Chronic stress–
induced epinephrine enhances LDHA-dependent metabolic 
activity, which increases lactate and augments USP28 that 
serves to stabilize the MYC protein. The data further revealed 
that MYC transactivates the SLUG promoter to enhance breast 
Figure 5. LDHA generating lactate enhances the USP28 signaling. (A) Immunoblots of siNC and siLDHA MDA-MB-231 cells treated with CHX for the 
indicated times. Intensity of USP28 expression for each time point was quantified by densitometry and plotted against time (right panel). (B) Immuno-
blots of MCF-7 cells treated for 5 days with Epi and/or siLDHA followed by incubation with or without MG132 for 6 hours. (C) Ubiquitin assays of 293T cells 
transfected with ubiquitin (Ubi) and siLDHA followed by treatment with Epi. (D) Immunoblots of MDA-MB-231 cells treated with the indicated concentra-
tions of sodium oxamate (Oxa) for 48 hours. (E) Immunoblots of MDA-MB-231 and MCF-7 cells treated with lactate (Lac) for 72 hours. (F) Immunoblots of 
MDA-MB-231 cells transfected with USP28 WT or C171A and then treated with lactate for 72 hours. (G) Immunoblots of immunoprecipitation experiments 
of 293T cells transfected with USP28 WT or C171A and then treated with lactate for 72 hours. (H) MDA-MB-231 cells were treated with lactate, hydrochloric 
acid (HCl), and acetic acid (HAC) for 72 hours. Expression of the indicated proteins was examined by immunoblotting. (I) Snapshot structures of USP28 
interacting with MYC motif extracted from constant-pH MD simulations at 2 representative pH conditions. Gray cartoons, USP28; green cartoons, MYC; 
blue spheres, Lys51 and Lys52 on MYC motif; red spheres and yellow spheres, His600 and Cys171 of USP28, respectively. (J) Lactate levels in serum of Ctrl (n = 
15) or stress (n = 20) mice (Student’s t test). (K) Model of chronic stress–mediated USP28 stabilization through decreased pH caused by LDHA generating 
lactate. Data are representative of at least 3 independent experiments. Data represent mean ± SEM; ***P < 0.001.
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Figure 6. Clinical relevance of LDHA expression under chronic stress. (A) Representative immunohistochemistry photomicrographs of tissues stained with 
indicated antibodies in patients with breast cancer (Epilo, n = 42; and Epihi, n = 41). Scale bar: 50 μm; original magnification, ×20, ×40, ×96 (enlarged insets). 
(B) Immunoblot analysis of proteins in breast cancer tissues (T) and adjacent normal breast tissues (N); n = 5. (C) Expression of mRNA for the indicated 
genes in MDA-MB-231-2D cells or spheres was measured by quantitative reverse transcriptase PCR; n = 3 (Student’s t test). (D) Kaplan-Meier estimates of 
overall survival and disease-free survival of patients with breast cancer, according to the serum Epi concentrations (Epilo, n = 42; and Epihi, n = 41). Eighty-
three patients were in the data set (log-rank test). (E) Kaplan-Meier estimates of overall survival and disease-free survival of patients with breast cancer, 
according to LDHA expression (LDHAlo, n = 30; and LDHAhi, n = 41). Seventy-one patients were in the data set (log-rank test). (F) Kaplan-Meier estimates 
of overall survival and disease-free survival of patients with breast cancer expressing high or low LDHA together with high or low serum Epi. Seventy-one 
patients were in the data set (log-rank test). Data are representative of at least 3 independent experiments. Data represent mean ± SEM; ***P < 0.001.
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hormone, epinephrine, stimulates glycogenolysis by activating 
glycogen synthase and increasing insulin-stimulated glucose 
uptake (33). In our experiments, epinephrine-treated cells consis-
tently increased glucose and lactate levels and reduced cellular 
ATP levels. Furthermore, chronic exposure to epinephrine pro-
motes the establishment of immunosuppressive microenviron-
ments through the induction of a COX2-dependent pathway (34). 
Epinephrine can also enhance antiapoptotic functions through 
cAMP-dependent phosphorylation of BAD (35). In addition, 
inhibiting LDHA, is a potential treatment for the stress-associ-
ated increase in breast cancer.
A substantial body of literature describes the effect of chronic 
stress on tumor progression. Stress-induced hormones control 
a number of important biological processes, such as metabolic 
events, immune activity, and apoptosis. Cortisol, a key stress hor-
mone, improves the hypoglycemic profile by promoting glucone-
ogenesis (31) and endoplasmic glucose production via pyridine 
nucleotide redox reactions (32). Similarly, another vital stress 
Figure 7. Vitamin C reverses chronic stress–induced breast cancer stem-like properties in vivo and in vitro. (A) US drug collection screening: MDA-MB-231 
cells stably expressed with pEGFP-LDHA were treated with 1280 drugs. Fluorescence intensities were examined. n = 3. (B) Representative heatmap of 
LDHA expression after treatment with the 18 candidate compounds; n = 3. Heatmap colors represent relative LDHA protein levels as indicated by the color 
key. (C) Immunoblot analysis of MDA-MB-231 and MCF-7 cells treated with vitamin C and/or Epi for 5 days. (D) Lactate levels were examined in the cell 
culture media of MDA-MB-231 cells in C; n = 3 (Student’s t test). (E) Representative spheroid images formed by single cells with vitamin C and/or Epi; n = 3. 
Scale bar: 50 μm. Bottom left panel shows distribution patterns of sphere diameter. Bottom right panel shows the number of spheres (d > 50 μm) (1-way 
ANOVA). (F) Tumor growth curves of indicated treatments of mice; n = 5 (1-way ANOVA). (G) Model of targeting chronic stress–mediated cancer stem-like 
traits by vitamin C. Data are representative of at least 3 independent experiments. Data represent mean ± SEM; *P < 0.05, **P < 0.01.
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which norepinephrine contributes to cancer stem-like properties 
and glucose metabolism is worth exploring further.
The transcription factor SLUG is a member of the Snail family 
that is essential for embryonic development (40, 41). Emerging evi-
dence demonstrates that SLUG plays an essential role in metastasis 
due to its endogenous overexpression in a variety of cancers (42, 43). 
SLUG is also a key protein that controls cancer cell stemness (44). 
Using Affymetrix Human PrimeView to perform large-scale expres-
sion profile analysis followed by comparison with the array data (fold 
change >2, Q < 0.05) with a stem cell gene set, we found that SLUG 
expression was significantly increased in mice treated with epineph-
rine. MYC activates a diverse group of genes that are known to pro-
mote cell growth and proliferation as part of a heterodimeric com-
plex with the protein MAX. The MYC-MAX heterodimer is capable 
of binding specific DNA sequences, such as the E-box sequence 
CACGTG (45, 46). In our studies, analysis through the JASPAR data-
base first confirmed that MYC activates SLUG transcription to stim-
ulate CSCs. These results are consistent with the previous finding 
that MYC binds directly to the SLUG DNA sequence –412 to –408 to 
transactivate its expression in breast cancer.
An unbiased search screen has been reported for MYC, from 
which we determined that the deubiquitinase USP28 directly sta-
bilizes the MYC protein in our chronic stress system. USP28 is a 
USP member of the DUB family, which has 4 known domains. 
Previous studies have shown that USP28 does not bind to MYC 
directly but rather binds MYC through interaction with FBW7 (47). 
Emerging evidence demonstrates that USP28 can bind and pro-
mote deubiquitination of MYC in the absence of FBW7 in intesti-
nal crypt stem cells (29). Importantly, our results establish that the 
chronic stress facilitated tumor angiogenesis through β-adren-
ergic activation of the cAMP/PKA signaling pathway in vivo and 
thereby promoted tumor growth (5). Stress-induced hormones, 
especially norepinephrine and epinephrine, protected the ovar-
ian tumor cells from anoikis and promoted their proliferation 
by phosphorylating focal adhesion kinase (FAK) at Y397 in vitro 
and in vivo (36). Consistently, we demonstrate that chronic stress 
increases epinephrine levels to promote tumorigenesis and cancer 
stem-like traits via activation of the LDHA/USP28/MYC/SLUG 
signaling axis in a mouse model.
Our data showed that high epinephrine in patient serum was 
positively associated with high LDHA, USP28, MYC, and SLUG 
expression and conferred lower overall survival and disease-free 
survival rates compared with those of patients with low epineph-
rine levels. In addition, epinephrine levels are not constant and 
can be influenced by activities such as exercise. Tumor-bearing 
mice with access to running wheels showed reduced growth of ER- 
positive breast tumors via activation of the Hippo signaling path-
way, a known regulator of cancer stem cells (37). The exercise- 
induced epinephrine surge and IL-6 suppress tumor growth and 
development through NK cell mobilization and redistribution (38, 
39). These studies reveal that high-intensity exercise markedly 
upregulates epinephrine to an extremely high level, which may 
lead to suppression of cancer. Hence, the comprehensive influence 
on epinephrine levels should be carefully evaluated in the further 
patient outcome and drug intervention. Our results also show that 
norepinephrine but not cortisol moderately enhanced the expres-
sion of self-renewal regulators (NANOG, OCT-4, and β-catenin) 
and glycolysis enzymes (PFKM and HK2). The mechanism by 
Table 2. Serial dilution tumorigenesis
Inoculation CtrlA StressA
CtrlB StressB ProB Pro + stressB CtrlB StressB ProB Pro + stressB
1 × 102 20% 40% 20% 20% 60% 60% 20% 40%
1 × 103 20% 60% 20% 40% 80% 100% 40% 60%
1 × 104 60% 80% 60% 40% 100% 100% 60% 80%
1 × 105 80% 80% 60% 60% 100% 100% 60% 80%
Serially diluted tumor cells from primary-treated mice (Ctrl and Stress) were subcutaneously inoculated at 4 different sites into each group of mice. 
Statistical analysis of tumorigenesis with indicated cell numbers and different treatments is shown. APrimary treatment of mice; Bsecondary treatment of 
mice. n = 5.
 
Table 3. Serial dilution tumorigenesis
Inoculation ProA Pro + stressA
CtrlB StressB ProB Pro + stressB CtrlB StressB ProB Pro + stressB
1 × 102 20% 40% 0% 20% 20% 40% 0% 20%
1 × 103 40% 60% 0% 40% 20% 40% 20% 40%
1 × 104 60% 80% 20% 60% 80% 80% 60% 80%
1 × 105 80% 80% 60% 80% 100% 100% 80% 100%
Serially diluted tumor cells from primary-treated mice (Pro and Pro + stress) were subcutaneously inoculated at 4 different sites into each group of mice. 
Statistical analysis of tumorigenesis with indicated cell numbers and different treatments is shown. APrimary treatment of mice; Bsecondary treatment of 
mice. n = 5.
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unknown. Our results reveal that LDHA induces glucose meta-
bolic disorders and stabilizes USP28 expression. However, the 
detailed mechanism by which LDHA stabilizes USP28 expression 
needs to be further explored.
The LDHA inhibitor sodium oxamate is known to be an effec-
tive anticancer agent in many types of cancer, including breast 
(53–56), non–small cell lung (57), and gastric cancer (58). How-
ever, the clinical application of sodium oxamate has been limited 
because of its high therapeutic doses and relatively low poten-
cy (59–61). As a result, new medications are urgently needed to 
replace sodium oxamate for targeting LDHA and to reverse the 
chronic stress–derived breast cancer stem-like phenotype. Using 
an FDA-approved high-throughput drug screen that includes 1280 
drugs, we identified vitamin C as one of 18 molecules that lowered 
LDHA expression. Recent reports support our findings that vita-
min C is an effective anticancer agent. For example, high levels 
of vitamin C can selectively kill KRAS- and BRAF-driven colorec-
tal cancer cells by inducing oxidative stress, suppressing glycoly-
sis and the subsequent energy crisis (62). High-dose intravenous 
vitamin C also promotes cell death through depletion of NAD+ and 
inhibits motility and mitosis by increasing α-tubulin acetylation in 
pancreatic cancer (63). In addition, physiological-level vitamin C, 
acting as an antioxidant, increases the activity of TET enzymes to 
rebuild 5-hydroxymethylcytosine (5hmC) content, leading to the 
inhibition of invasiveness and clonogenic growth in melanoma 
(64). Low-dose vitamin C as a cofactor of TET enhances the apop-
tosis effect of DNMT inhibitors via enhancing immune signals in 
the treatment of hematological cancers (65). It is also noteworthy 
that vitamin C–treated stressed mice display a significant reduc-
tion in depressive-like behaviors (66). Furthermore, vitamin C 
specifically targets breast cancer stem cells via suppression of gly-
colysis due to loss of mitochondrial function (67). Vitamin C coun-
teracts miR-302/367 to suppress breast cancer stem cell repro-
gramming via decreasing TET1 gene expression (68). Although 
a recent study indicated that high-dose vitamin C selectively 
induced DNA damage on glioblastoma stem cells rather than dif-
ferentiated tumor cells, it also displayed the cellular toxicity on 
neural stem and progenitor cells (69). In our study, vitamin C sup-
pressed stress-induced LDHA, thus altering the lactate production 
to inhibit the USP28/MYC/SLUG axis in breast cancer stem cells.
Methods
Cell lines and culture conditions. Human breast cancer cell lines (MDA-
MB-231 and MCF-7) and 293T were purchased from the American 
Type Culture Collection (ATCC). These cell lines were authenticated 
at ATCC before purchase by standard short tandem repeat DNA-typ-
ing methodology. The murine mammary carcinoma cell line E0771 
was purchased from BeNa Culture Collection. The Py8119 cell line 
was provided by Suling Liu (Fudan University, Shanghai, China). The 
MDA-MB-231, E0771, and 293T cell lines were maintained in Dulbec-
co’s modified Eagle medium (DMEM; Invitrogen) supplemented with 
10% FBS (Invitrogen Corp.). The MCF-7 cell line was maintained in 
Eagle’s minimum essential medium (Invitrogen Corp.) supplemented 
with 10% FBS and 0.01 mg/ml human recombinant insulin. The 
Py8119 cell line was maintained in F12K nutrient media (HyClone) 
supplemented with 5% FBS. Each cell line was cultured in standard 
medium as recommended by ATCC. All cells were incubated at 37°C 
MYC MBI domain (1–95 amino acids) interacts directly with the 
USP domain (160–652 amino acids) of USP28. Its crystal structure 
showed that USP28 interacts with MYC through C171 and the MBI 
domain. Moreover, recent findings show the ubiquitination sites of 
MYC, including Lys 51, Lys 148, Lys 389, and Lys 430, in response 
to DNA damage using quantitative proteomics (48). Our compu-
tational simulation analysis also revealed that USP28 displayed 
possible binding to Lys 51 and Lys 52 of MYC, which implied that 
ubiquitination might be involved in USP28’s binding to MYC.
Cancer cells show profound metabolic changes, mainly com-
prising aerobic glycolysis, de novo lipid biosynthesis, and glu-
tamine-dependent anaplerosis, all of which provide energy and 
building blocks to sustain their high proliferation rates (49). The 
first noted change in cancer metabolism was in aerobic glycolysis, 
known as the Warburg effect. It is characterized by the ATP gen-
eration pattern shifting from oxidative phosphorylation to glycol-
ysis, even under normal oxygen concentrations (50). This effect 
is regulated by PI3K, hypoxia-inducible factor (HIF), p53, MYC, 
and AMP-activated protein kinase (AMPK)/liver kinase B1 (LKB1) 
pathways (51). To analyze whether glycolysis is involved in the 
effects of epinephrine on breast cancer cells, we used CE-MS to 
examine changes in metabolites in stressed cells. This approach 
revealed a significant enrichment in metabolic processes. In gly-
colysis, LDHA executes the final step of aerobic glycolysis signal-
ing by converting pyruvate to lactate. Deregulation of LDHA has 
been reported in many cancers (18–20, 52), but the underlying 
biochemical process by which LDHA acts on cancer cells has been 
Table 4. Altered genes in microarray data
117 Altered genes in microarray data (fold change >2, P < 0.05)
ABCC2 ABCC3 ABCG2 ABLIM3 ADM
AFAP1L1 AHNAK2 AKR1C1 AKR1C2 ANXA8
ANXA8L1 ANXA8L2 ARG2 ARHGAP22 ASNS
ATP6V0A4 B3GNT5 BANK1 BCL2A1 BDNF
BMP4 C15orf48 CALB2 CDCP1 COL13A1
COL5A1 CORO2B CREB5 CSGALNACT1 CYP1B1
DNMBP DUSP1 DUSP5 ECM1 EFEMP1
ENPP1 ENPP2 EPSTI1 F3 FAM129A
FAM83A FHL1 FOXQ1 FRMD4A FRMD5
GADD45A GJB2 GKN2 GNG11 HIST1H2AC
HIST1H2BD HIST1H2BK HK2 HMGA1 HMGA2
HMGB3 HOXB3 HS3ST1 IER5L IL7R
INSL4 ISG15 ITGA2 JUN KRT81
KRTAP2-3 KRTAP2-4 LAMB3 LCP1 LGALS8
SYNE3 LPAR1 NDRG1 NQO1 NRG1
NRP1 OASL OGFRL1 OSBPL10 OTUB2
PARD6B PCDH7 PDE2A PITPNC1 PLAT
PLOD2 PTGS2 PTPRF PTX3 RARRES3
RASGRP3 RGCC RGS17 S100P SDC2
SLPI SLUG SOX9 STC1 STEAP1
STEAP1B SUSD2 TFAP2C TGFBI TMCC3
TMEM154 TMEM158 TNC TNFAIP3 TNFRSF21
TRIO TSPAN5 TSPAN8 TXNIP WHSC1
WISP2 ZNF185
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injected into the fat pads of C57BL/6 mice. To perform 
serial dilution assays, 102, 103, 104, and 105 MDA-
MB-231 tumor cells were injected s.c. into each dorsal 
flank. Tumor sizes were measured in perpendicular 
dimensions using calipers. Volumes were estimated 
using the formula (a2 × b)/2, where a is the shorter of 
the 2 dimensions and b is the longer. The P value was 
obtained by comparisons between the control and 
treatment groups at each time point. Detailed  informa-
tion on the mice is provided in Supplemental Table 5.
For the metastatic mouse model, 4- to 6-week-old 
female BALB/c mice were injected with MDA-MB-231 
cells (5 × 105 in 150 μl PBS) infected with an empty vec-
tor, shMYC, or shSLUG into the tail vein. Before being 
euthanized at 5 weeks following injection, all mice 
were subjected to a CT scan.
Plasmid constructs and transfection. Plasmids 
encoding human MYC (full-length, 1–215, 1–148, 1–95 
aa) were generated by PCR amplification and subcloned 
into pcDNA6 expression vectors. Plasmids expressing 
the SLUG promoter (–2121–0, –1497–0, –997–0, –496–0, 
–200–0 bp) were generated by PCR amplification and 
subcloned into pGL3-basic expression vectors. Detailed 
information on the plasmid constructs is provided in 
Supplemental Table 8. Fidelity of all vectors was con-
firmed by DNA sequencing. Expression plasmids were 
transfected into cells using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s instructions. OE-USP28 was 
from Lingqiang Zhang (Beijing Institute of Lifeomics, Beijing, China). 
USP28 shRNA expression plasmids and USP28 (C171A) and USP28 
deletion constructs were gifts from Binhua P. Zhou (University of Ken-
tucky, College of Medicine, Lexington, Kentucky, USA). LDHA shRNA 
expression plasmids and pEGFP-LDHA were provided by Qingkai Yang 
(Dalian Medical University, Dalian, China).
Gene knockdown with shRNA. Knockdown of genes was performed 
with specific shRNAs delivered using a lentiviral system purchased 
from Sigma-Aldrich Corp. according to the instructions provided by 
the manufacturer. In brief, to generate the lentivirus containing the 
specific shRNA, 293T cells were cotransfected with 2.5 mg pMD2.G 
and 7.5 mg psPAX2 compatible packaging plasmids and 10 mg of 
pLKO.1 plasmid bearing the specific shRNA for 24 hours. Culture 
medium containing the generated lentiviruses was collected and 
stored at –80°C as aliquots for further use. To deliver the specific 
in a humidified incubator containing 5% CO2. All cell lines are listed in 
the Supplemental Table 4.
Chronic stress mouse model. Stressed mice were restrained in a 
confined space that prevented them from moving freely or turning 
around but did not unduly compress them. This method induces 
chronic stress as evidenced by neuroendocrine activation and induc-
tion of both anxiety- and depression-like behaviors but does not 
cause pain or wounding (5). All mice were subjected to a pretreat-
ment of stress for 7 days to acclimate these conditions for the study. 
Then, we inoculated MDA-MB-231 cells (1 × 106) into the pretreated 
mice and randomly assigned them to control conditions or daily 
restraint stress for a maximum length of 30 days.
Animal studies. Four- to six-week-old NOD/SCID and C57BL/6 
mice were used in each experimental group. MDA-MB-231 cells (1 × 106 
in PBS/Matrigel [1:1]) were injected s.c. into both flanks of NOD/SCID 
mice. E0771 and Py8119 tumor cells (5 × 106 in PBS/Matrigel [1:1]) were 
Table 5. Association of plasma epinephrine level with clinical and pathological 
characteristics of breast cancer patients
Variable All cases N (%) Plasma Epi level PA
Low High
HER2 0.814
<–/+ 55 (66.3) 29 26
≥–/+ 28 (33.7) 14 14
PR 0.903
≤+ 40 (48.2) 21 19
≥++ 43 (51.8) 22 21
ER 0.484
≤+ 28 (33.7) 13 15
≥++ 55 (66.3) 30 25
Tumor stage 0.584
T1 23 (27.7) 10 13
T2 43 (51.8) 24 19
T3 13 (15.7) 6 7
T4 4 (4.8) 3 1
Node stage 0.632
N0 33 (39.8) 19 14
N1 20 (24.1) 11 9
N2 19 (22.9) 9 10
N3 11 (13.2) 4 7
Aχ2 test; n = 83. <–/+, HER2–; ≥–/+, HER2+; ≤+, PR– or ER–; ≥++, PR+ or ER+.
Table 6. Results of multivariate Cox proportional hazards analysis for overall survival and disease-free survival in breast cancer patients
Variable For OS For DFS
Hazard ratio 95% Confidence interval P Hazard ratio 95% Confidence interval P
HER2 <–/+ (vs. ≥–/+) 0.679 0.235–1.966 0.476 1.174 0.437–3.150 0.751
PR ≤+ (vs. ≥++) 0.872 0.326–2.329 0.785 1.023 0.410–2.553 0.961
ER ≤+ (vs. ≥++) 0.886 0.362–2.168 0.79 0.953 0.411–2.209 0.910
Tumor stage T3 + T4 (vs. T1 + T2) 1.884 1.110–3.199 0.019 2.343 1.415–3.882 0.01
Node stage N2 + N3 (vs. N0 + N1) 1.350 0.883–2.064 0.165 1.787 1.188–2.689 0.05
Epilo (vs. Epihi) 0.322 0.125–0.828 0.019 0.171 0.063–0.465 0.01
n = 83. OS, overall survival; DFS, disease-free survival. <–/+ , HER2–; ≥–/+, HER2+; ≤+,PR– or ER–; “≥++, PR+ or ER+. 
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ing to the percentage of high-staining cells per field: negative (score 
0), 25% (score 1), 26%–50% (score 2), 51%–75% (score 3), and 76%–
100% (score 4). All immunohistochemical staining was evaluated and 
scored by at least 2 independent pathologists. Details on the Critical 
Commercial Assays are provided in Supplemental Table 3.
Pharmacological studies. Cells were maintained in DMEM for 8–12 
hours that was followed by DMEM supplemented with 2% FBS for 5 
days with different pharmaceutical treatments. The concentration 
of all drugs was chosen based on successful activation/inhibition in 
previous publications: epinephrine (10 nM), propranolol (10 μM), and 
ICI118,551 (10 μM). For other drugs, cells were maintained in 10% 
DMEM: vitamin C (1 μM), actinomycin D (5 μg/ml), cycloheximide 
(200 μg/ml). For mice, epinephrine (2 mg/kg/d, s.c.), propranolol (2 
mg/kg/d, i.p.), and ICI118,551 (25 μM/100 μl, i.p.) were injected 7 
days before tumor cell injection. The control group of mice received 
an equal volume of PBS. Detailed information on the chemicals used 
are listed in Supplemental Table 2.
Metabolic assays. Glucose uptake, lactate production, and ATP con-
centrations were measured by assay kits from BioVision. All procedures 
were performed as recommended by the manufacturer. Information 
on the Critical Commercial Assays is provided in Supplemental Table 3.
Metabolomics analysis. Cells were washed with 10 ml mannitol 3 
times. This was followed by addition of 1 ml methanol containing 10 
μM of d-camphor-10-sulfonic acid sodium salt as internal standards 
to each plate. Cells were then scraped (Corning) and transferred to a 
5-ml Eppendorf tube. One milliliter of chloroform was then added to 
the tube, followed by vortexing for 30 seconds. Water in the amount of 
400 μl was subsequently added to form a 2-phase system. After vor-
texing for 1 minute, the mixture was left to stand for 5 minutes and 
then centrifuged at 15,000 g for 15 minutes at 4°C. Subsequently, 450 
μl of the upper layer was transferred and was filtered via centrifuga-
tion through a 5-kDa-cutoff filter (Millipore) to remove proteins (9100 
g, 3 hours at 4°C). The filtrate was lyophilized and stored at –80°C. 
Before CE-TOF/MS analysis, dried samples were reconstituted in 
Milli-Q water (MilliporeSigma) containing 50 μM of trimesic acid and 
2-naphtol-3,6-disulfonic acid disodium salt as internal standards to 
adjust for migration time in the anion mode.
Screening of US drug collection of compounds against LDHA. MDA-
MB-231 cells were stably infected with LDHA that was subcloned 
into the pEGFP-C1 vector and then plated onto 96-well plates. Indi-
vidual drugs were added to each well for 6 (1 μM, T1; or 2 μM, T2) 
and 12 hours (1 μM, T3) at 50% confluence. After washing of cells 
with PBS, LDHA expression in infected cells was determined by flu-
orescence detection.
In vitro limiting dilution assay. Limiting dilution assay was per-
formed as described previously (70). Briefly, dissociated primary cells 
were seeded in 96-well plates at densities of 1, 2, 4, 8, 16, 32, and 64 cells 
per well. Wells with no sphere were counted for each group after 7 days.
Statistics. Each in vivo and in vitro experiment was performed in 
triplicate and repeated at least 3 times. Statistical analyses were per-
formed with SPSS software (version 16.0) or GraphPad Prism 6.0 
(GraphPad Software Inc.). Differences between variables were assessed 
by 2-tailed Student’s t test, 1-way ANOVA, and χ2 test, where appropri-
ate. Data were expressed as mean ± SEM. P values less than 0.05 were 
considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
Accession number. The mRNA array data were deposited in the 
GEO database with accession number GSE116781.
shRNA construct, approximately 10% confluent cells were infected 
with lentiviruses bearing the specific shRNA in growth medium con-
taining 8 mg/ml Polybrene and were incubated at 37°C for 24 hours. 
Transfected cells were subsequently selected with 2 mg/ml puromycin 
at approximately 50% confluence. Details on the shRNAs are provided 
in Supplemental Table 7.
Quantitative reverse transcriptase PCR. Total RNA was extracted 
using TRIzol reagent (Invitrogen) and used to generate cDNA by 
EasyScript One-Step gDNA Removal and cDNA Synthesis SuperMix 
(TransGen Biotech) with an oligo-dT primer. Real-time reverse tran-
scriptase PCR was performed using SYBR Select Master Mix (Life 
Technologies) as recommended by the manufacturer. ACTB was used 
as the internal control. All primers are listed in Supplemental Table 6.
Immunoprecipitation and immunoblot assays. Cells were treated 
with the proteasome inhibitor MG132 (10 μM) for 6 hours before cell 
lysis. Coimmunoprecipitation was performed using 1 μg of antibod-
ies and 200–500 μg of exogenous protein lysates. Protein A/G PLUS- 
Agarose immunoprecipitation reagent was then added, and this incuba-
tion was continued for 8 hours at 4°C. Beads were washed 3 times with 
1 ml of coimmunoprecipitation buffer and subjected to Western blot 
analysis. Cells were lysed on ice in RIPA buffer, and protein concentra-
tions were determined using Coomassie Brilliant Blue. Equal amounts 
of protein were subjected to electrophoresis on 10% gradient SDS-
PAGE gels followed by immunoblot assays with the antibodies listed in 
 Supplemental Table 1. See Supplemental data for the unedited blots.
Luciferase reporter assay. Cells were plated at a density of 1 × 105 cells 
per well in 24-well plates. After 20 hours, cells were transfected with SLUG 
promoter–driven luciferase constructs (pGL3-SLUG) or control (pGL3- 
Basic) luciferase constructs. Fluc/Rluc activities were measured using 
the Dual Luciferase Reporter Assay System (Promega). Information on the 
Critical Commercial Assays is provided in Supplemental Table 3.
Mammosphere culture. Sphere formation was performed in 
ultralow attachment plates (Corning) with medium supplemented 
with 2% B27, 20 ng/ml bFGF, and 20 ng/ml EGF. MDA-MB-231 and 
MCF-7 cells were seeded at a density of around 2 cells/μl and cultured 
at 37°C with 5% CO2. After 14 days, spheres greater than 50 μm diam-
eter were counted at ×40 magnification (Olympus). The reagents used 
are listed in Supplemental Table 2.
Chromatin immunoprecipitation. ChIP was performed using 
ChIP-IT Express Chromatin Immunoprecipitation Kits (Active Motif) 
according to the manufacturer’s protocol. See Supplemental Methods 
for details. Detailed information on the Critical Commercial Assays 
is provided Supplemental Table 3, and the primers used are listed in 
Supplemental Table 6.
Immunohistochemical staining and statistical analysis. Paraffin- 
embedded tissue blocks were used for immunohistochemical stain-
ing. Paraffin-embedded tissue specimens were sectioned, deparaffin-
ized in xylene, and rehydrated, followed by antigen retrieval in sodium 
citrate, and the sections were then processed using SPlink Detection 
Kits (ZSGB-BIO) according to the manufacturer’s instructions. The 
sections were incubated with primary antibodies (1:200 dilution) 
overnight at 4°C. Specimens were stained using a DAB kit (ZSGB-BIO) 
until the desired stain intensity was developed. Sections were then 
counterstained with hematoxylin, dehydrated, and mounted. Staining 
intensity and extent of staining were graded as follows: negative (score 
0), bordering (score 1), weak (score 2), moderate (score 3), and strong 
(score 4). Extent of staining was also grouped into quantiles accord-
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